Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16914377 | 0.85 | CYP11B1 (0.40) | CRBNDDB1GAAGFERKDM4E | |
| SCHEMBL16600611 | 0.82 | CRBN (0.32) | CRBNDDB1 | |
| SCHEMBL26656803 | 0.80 | SLC6A2 (0.34) | CRBN | |
| SCHEMBL38658950 | 0.79 | — | — | |
| SCHEMBL17101524 | 0.79 | DDB1 (0.33) | CRBNDDB1 | |
| SCHEMBL29257295 | 0.78 | DDB1 (0.33) | CRBNDDB1 | |
| SCHEMBL30674755 | 0.77 | DDB1 (0.33) | CRBNDDB1MGLL | |
| SCHEMBL2635991 | 0.76 | DDB1 (0.39) | CRBNDDB1ALDH1A1 | |
| SCHEMBL18319559 | 0.76 | CRBN (0.35) | CRBNDDB1GAAGFERKDM4E | |
| SCHEMBL7010905 | 0.74 | USP2 (0.46) | CRBNDDB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789404-B1 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | CRBN 429/4885DDB1 3915/4885GAA 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.